Drug Selection, Dosage Adjustment, and Potential Interaction of Antihypertensive and Antidiabetic for Chronic Kidney Disease with Hemodialysis

Authors

  • Nisa Maria Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, 16424, Indonesia ,
  • Ferlina Vidyananda Susilo Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, 16424, Indonesia ,
  • Mayannaria Simarmata Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, 16424, Indonesia ,

DOI:

https://doi.org/10.35814/jifi.v21i2.1484

Keywords:

Antidiabetic, antihypertensive, chronic kidney disease, drug related problems, hemodialysis

Abstract

Antihypertensive and antidiabetic drugs in CKD patients on hemodialysis may cause medication-related problems requiring monitoring. This study aimed to evaluate the selection, dosage, and potential drug interactions of antihypertensive and antidiabetic drugs in stage 5 CKD patients with hypertension and/or type 2 diabetes mellitus undergoing hemodialysis in a hospital in Jakarta. A crosssectional study used the medical records of adult in patients from January - December 2022 with a total sampling method. Out of 101 patients, 97.0% received appropriate drug selection. Dosage adjustments were appropriate in 74.3% of cases. Potential drug interactions between antihypertensive and antidiabetic drugs were found in 90.1% of patients, mostly pharmacodynamic interactions, moderate severity, and requiring monitoring. Statistical analysis showed that age, gender, number of drugs, and length of stay were not associated with the appropriateness of antihypertensive and antidiabetic drug selection (p>0.05). However, there was a relationship between number of drugs (p=0.033; OR=2.996) and length of stay (p=0.024; OR=3.171) with the appropriateness of drug dosage. The length of stay was also associated with potential drug interactions (p=0.040; OR=8.426). Drug selection has been done well, but there is a need for improvement in monitoring dosage adjustments and potential drug interactions by pharmacists in the hospital.

References

Downloads

Published

2023-10-25

Issue

Vol. 21 No. 2 (2023): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.